Compare PARK & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | CLNN |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | United States |
| Employees | 1212 | 79 |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 85.7M |
| IPO Year | N/A | N/A |
| Metric | PARK | CLNN |
|---|---|---|
| Price | $18.45 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | 14.4K | ★ 607.3K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | $17.64 |
| Revenue Next Year | $6.17 | $19,516.77 |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $2.36 |
| 52 Week High | $21.60 | $13.50 |
| Indicator | PARK | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 50.61 |
| Support Level | $16.66 | $6.59 |
| Resistance Level | $19.14 | $6.92 |
| Average True Range (ATR) | 0.98 | 0.69 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 61.41 | 41.42 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.